Long-term patient survival in ANCA-associated vasculitis

2010/11/26 by Oliver Floßmann, Oliver Flossmann, Annelies Berden +17 · 31 citations
Medicine · Biochemistry, Genetics and Molecular Biology · #Cancer Cells and Metastasis #Vasculitis and related conditions #Angiogenesis and VEGF in Cancer

paper · doi:10.1136/ard.2010.137778

Citations

• A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation

Cited by

• EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update
• Mortality in ANCA-associated vasculitis: ameta-analysis of observational studies
• Preventing infections in immunocompromised patients with kidney diseases: vaccines and antimicrobial prophylaxis
• Characteristics and risk factors for infection in patients with ANCA-associated vasculitis: A systematic review and meta-analysis
• A stronger type I interferon signature distinguishes ANCA-associated vasculitis phenotypes and predicts kidney prognosis
• Patients’ experiences of managing their rare rheumatic disease
• The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis. [europepmc]
• High prevalence of autoantibodies to hLAMP-2 in anti-neutrophil cytoplasmic antibody-associated vasculitis. [europepmc]
• Genetically distinct subsets within ANCA-associated vasculitis. [europepmc]
• Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial. [europepmc]
• Predictors of treatment outcomes in ANCA-associated vasculitis with severe kidney failure. [europepmc]
• Proteinase 3-ANCA Vasculitis versus Myeloperoxidase-ANCA Vasculitis. [europepmc]
• Outcome and treatment of elderly patients with ANCA-associated vasculitis. [europepmc]
• Trends in Long-Term Outcomes Among Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis With Renal Disease. [europepmc]
• Neutrophil Extracellular Traps in ANCA-Associated Vasculitis. [europepmc]
• Mechanisms of Autoantibody-Induced Pathology. [europepmc]
• Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis. [europepmc]
• Pathogenetic and Clinical Aspects of Anti-Neutrophil Cytoplasmic Autoantibody-Associated Vasculitides. [europepmc]
• Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire. [europepmc]
• Epidemiology and Outcomes of Granulomatosis With Polyangiitis in Pediatric and Working-Age Adult Populations In the United States: Analysis of a Large National Claims Database. [europepmc]
• Risk factors for infectious complications of ANCA-associated vasculitis: a cohort study. [europepmc]
• Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis. [europepmc]
• Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated Vasculitis: a multi-center retrospective cohort study. [europepmc]
• All-cause and cause-specific mortality in ANCA-associated vasculitis: overall and according to ANCA type. [europepmc]
• Therapeutic Myeloperoxidase Inhibition Attenuates Neutrophil Activation, ANCA-Mediated Endothelial Damage, and Crescentic GN. [europepmc]
• Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. [europepmc]
• Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. [europepmc]
• French recommendations for the management of systemic necrotizing vasculitides (polyarteritis nodosa and ANCA-associated vasculitides). [europepmc]
• Platelet CXCL4 mediates neutrophil extracellular traps formation in ANCA-associated vasculitis. [europepmc]
• Effect of Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis: A Randomized Clinical Trial. [europepmc]
• Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan. [europepmc]